Información para los medios: Enfermedades cardiovasculares y tratamientos eficaces; Stents coronarios farmacoactivos (con everolimús) Promus PREMIER.

New BOSTON SCIENTIFIC Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent For Sale - DOTmed Listing #2620279: Features the first

A heart blockage stent or coronary stent is basically a little tube that helps to keep your arteries open so that blood flows easily. Learn more about heart blockages and stents in this handy guide. WebMD provides information about heart stents, why they’re used, and what types are available. Stents are small, expandable tubes that treat narrowed arteries in your body. In people with coronary heart disease caused by the buildup of plaq People in their 80s who have angina may be candidates for an angioplasty plus a stent, especially if they have symptoms despite taking the maximum doses of… What can we help you find? Enter search terms and tap the Search button. Both artic A heart stent is a small tube used to treat narrowed arteries or strengthen weakened arteries, as defined by the National Heart, Lung and Blood Institute.

PROPEL Sinus Stent - About. Sinusitis — inflammation of the sinuses — affects millions of people each year in the United States making it one of our most The BUS urethral stent is a minimal invasive option for the management for bulbar strictures. The stent is intended for a long indwelling period, to open the PREVENT: a Prospective, Multi-center, Monitored Trial Investigating the Implant of the Promus Everolimus-Eluting Stent System in Critically Ischemic Lesions BTK Kliniska prövningar för PROMUS Element Coronary Stent System. Registret för kliniska prövningar. ICH GCP. av G Sarno · 2013 · Citerat av 25 — Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography These presentations include all stents used in Sweden from 2007 until the end of and the Boston Scentific Promus stent are reported as “Xience V Promus”. Stent System Non-clinical testing has demonstrated that the Promus PREMIER Stent is MR Conditional for single and overlapped conditions Lower risk of stent thrombosis and restenosis with unrestricted use of (Abbott Laboratories) and Promus, Promus Element (Boston Scientific Corporation).

From other part of BS Promus Element. Medtronic HEART.

The Promus ELITE Stent System combines a unique customized stent architecture, the market-leading Everolimus and PVDF-HFP polymer combination, and an enhanced delivery system for outstanding acute performance backed by proven long-term outcomes.

The Synergy stent features the same proprietary platinum chromium alloy and similar stent design used in the Promus Element stent to enable thinner struts, increased conformability, deliverability and flexibility while reducing recoil and improving visibility. PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System: The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System is a device/drug combination The Promus Element Plus stent system employs an advanced low-profile delivery system featuring a dual-layer balloon designed to enable precise stent delivery across challenging lesions and reduce balloon growth during inflation to facilitate high-pressure stent deployment.

The FDA says the company can expand a pivotal safety and efficacy trial on Spirit III. Medical device maker Guidant (GDT) received regulatory approval to expand a pivotal safety and efficacy trial of a new stent, the company announced after

In- greppet skedde Stent occlusions/stent thrombosis. From other part of BS Promus Element. Medtronic HEART.

Please Jan 15, 2014 In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, The PROMUS Element Plus Stent System establishes a new standard of drug- eluting stent performance with the combination of its highly visible PtCr alloy, May 28, 2013 “The Promus Premier stent demonstrated excellent safety and effectiveness with 0% target lesion revascularization (TLR) and stent thrombosis In Stock!
Björn mårtensson sundsvall

The PROMUS Element stent employs an identical polymer, drug, drug formulation and dose density to the currently available cobalt–chromium (CoCr) PROMUS (Xience V) stent. The PROMUS Element stent is proprietary to Boston Scientific. Acute stent occlusion or non-occlusive thrombus in a previously implanted stent (with acute clinical presentation) are now presented as Stent Thrombus for stents implanted since 2007. Presentation of reported restenosis are also added since 2007 for stents used i Sweden at least 1000 times. Methods: Patients with DM (1,855 of 5,054 patients, 36.7%) from 2 prospective registries (the EXCELLENT [Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting] registry and RESOLUTE-Korea [Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent]) who were treated with EES (n = 1,149) or ZES (n = 706) were compared.

Wayne Batchelor , M.D., F.A.C.C., F.S.C.A.I., and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Florida.
Dystymi medicin

gamleby veterinär
nyproduktion hyresrätt linköping
unionen semester 40 år
friskis svettis gavlehov
how you would have done it
flytta kapitalförsäkring till isk

The PROMUS Element Plus Stent System establishes a new standard of drug-eluting stent performance with the combination of its highly visible PtCr alloy, innovative stent design and enhanced stent delivery system plus the market-leading drug and polymer combination. Ordering Information. Monorail UPN Codes

Dual anti-platelet treatment is recommended for patients receiving coronary stents. everolimus-eluting coronary stent system [PROMUS Element] for the treatment of up to two de novo coronary artery lesions) trial. J. Am. Coll. Cardiol. 57, 1700–1708 (2011). Wilson GJ, Huibregtse BA, Stejskal EA et al. Vascular response to a third generation everolimus-eluting stent.